Pulse Biosciences Inc PLSE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results
-
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors
-
Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System
-
Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences
-
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Pulse Biosciences, Inc. (NASDAQ: PLSE)
-
Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024
-
Pulse Biosciences Hit 2-Year High on FDA Status for Surgery System
-
Pulse Biosciences Gets FDA's Breakthrough Status for Surgery System
Trading Information
- Previous Close Price
- $16.10
- Day Range
- $15.97–16.90
- 52-Week Range
- $3.78–22.69
- Bid/Ask
- $16.07 / $16.02
- Market Cap
- $979.42 Mil
- Volume/Avg
- 185,266 / 218,798
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Value
- Total Number of Employees
- 56
- Website
- https://www.pulsebiosciences.com
Comparables
Valuation
|
Metric
|
PLSE
|
MXCT
|
SIBN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 32.72 | 1.70 | 3.70 |
Price/Sales | — | 8.18 | 3.97 |
Price/Cash Flow | — | — | — |
Price/Earnings
PLSE
MXCT
SIBN
Financial Strength
|
Metric
|
PLSE
|
MXCT
|
SIBN
|
|---|---|---|---|
Quick Ratio | 4.39 | 13.19 | 7.99 |
Current Ratio | 4.57 | 14.31 | 9.17 |
Interest Coverage | — | — | −12.97 |
Quick Ratio
PLSE
MXCT
SIBN
Profitability
|
Metric
|
PLSE
|
MXCT
|
SIBN
|
|---|---|---|---|
Return on Assets (Normalized) | −60.57% | −8.16% | −6.03% |
Return on Equity (Normalized) | −79.60% | −9.30% | −8.10% |
Return on Invested Capital (Normalized) | −69.89% | −13.01% | −8.97% |
Return on Assets
PLSE
MXCT
SIBN
Medical Instruments & Supplies Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Intuitive Surgical Inc
ISRG
| Kpqzqddtls | Sygn | $171.3 Bil | |||
| Becton Dickinson & Co
BDX
| Xcwtnqgc | Plmttj | $68.9 Bil | |||
| Alcon Inc
ALC
| Gxsxjzbx | Mslkyp | $48.1 Bil | |||
| ResMed Inc
RMD
| Mlclvwwjg | Lgwpjb | $34.3 Bil | |||
| Coloplast AS ADR
CLPBY
| Yqxwjjwktc | Bxfl | $28.7 Bil | |||
| West Pharmaceutical Services Inc
WST
| Jbrmvxqcty | Plvp | $21.5 Bil | |||
| The Cooper Companies Inc
COO
| Byvlcypx | Yplhfwz | $21.1 Bil | |||
| Hologic Inc
HOLX
| Hmwrqdwzl | Dtqvjbz | $18.6 Bil | |||
| Baxter International Inc
BAX
| Jvkpxbjgg | Bbntyr | $18.5 Bil | |||
| Align Technology Inc
ALGN
| Jtbstcyq | Jjywwk | $18.0 Bil |
United States